

11 May 2026

Biologics in Rheumatology

1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

• Abatacept [Orencia]	266
• Adalimumab [Humira]	253
• Adalimumab Biosimilars	839
• Apremilast [Otezla]	0
• Apremilast [Generic]	<5
• Baricitinib [Olumiant]	30
• Bimekizumab [Bimzelx]	57
• Certolizumab [Cimzia]	159
• Etanercept [Enbrel]	104
• Etanercept Biosimilars	392
• Filgotinib [Jyseleca]	<5
• Golimumab [Simponi]	95
• Golimumab Biosimilar	0
• Guselkumab [Tremfya]	14
• Infliximab [Remicade]	73
• Infliximab Biosimilars	48
• Ixekizumab [Taltz]	141
• Risankizumab [Skyrizi]	<5
• Rituximab [MabThera]	78
• Rituximab Biosimilars	201
• Sarilumab [Kevzara]	<5
• Secukinumab [Cosentyx]	250
• Tocilizumab [Ro Actemra]	223
• Tocilizumab Biosimilars	0
• Tofacitinib [Xeljanz]	30
• Upadacitinib [Rinvoq]	139
• Ustekinumab [Stelara]	<5
• Ustekinumab Biosimilar	<5

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

11 May 2026

2. Could you please provide the numbers of patients treated for Psoriatic Arthritis (PsA) ONLY in the last 3 months with the following drugs:

- **Abatacept [Orencia]**
- **Adalimumab [Humira]**
- **Adalimumab Biosimilars**
- **Apremilast [Otezla]**
- **Apremilast [Generic]**
- **Bimekizumab [Bimzelx]**
- **Certolizumab [Cimzia]**
- **Etanercept [Enbrel]**
- **Etanercept Biosimilars**
- **Golimumab [Simponi]**
- **Golimumab Biosimilar**
- **Guselkumab [Tremfya]**
- **Infliximab [Remicade]**
- **Infliximab Biosimilars**
- **Ixekizumab [Taltz]**
- **Risankizumab [Skyrizi]**
- **Secukinumab [Cosentyx]**
- **Tofacitinib [Xeljanz]**
- **Upadacitinib [Rinvoq]**
- **Ustekinumab [Stelara]**
- **Ustekinumab Biosimilar**

The above information is not recorded and to provide it would require a manual trawl of individual patient records, which would take more than 18 hours work.

Belfast Trust considers that the cost of retrieving the information would be above the 'Appropriate Limit', as defined by the Freedom of Information Act under Section 12. Section 12 of the Freedom of Information Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit. The limit has been specified as £450 for public authorities such as Belfast Trust. This represents the cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.